Close menu




Pharma

Photo credits: pixabay.com

Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST

Bayer, Defence Therapeutics, Novavax - Major events

  • Biotechnology
  • Pharma

The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.

Read

Commented by Fabian Lorenz on May 9th, 2024 | 08:00 CEST

Stocks facing revaluation! Nel ASA, Bayer, Power Nickel with potential

  • Mining
  • Gold
  • Silver
  • Nickel
  • Pharma
  • renewableenergies

Relief for Bayer. In the US, the Company has won a victory in the dispute over compensation for illnesses caused by the chemical PCB. Is it groundbreaking and the start of a revaluation of the share? A revaluation already seems to be underway at Power Nickel. Following sensational drilling results, the share price soared. Surprisingly, gold, silver and copper were also found. Against this backdrop, the share appears to be favorably valued. Does this also apply to Nel? After all, the share price has risen by around 20% in just a few weeks. Is there new hope for the hydrogen pioneer? Or are today's figures from industry peer Plug Power threatening a new sell-off?

Read

Commented by André Will-Laudien on May 9th, 2024 | 07:00 CEST

Biotech and pharma stocks finally follow suit! Novo Nordisk, Bayer, BioNTech, Vidac Pharma and Evotec on the buy list

  • Biotechnology
  • Pharma

Things looked very different at the beginning of the year. After a brilliant rally in the Nasdaq Biotech Index at the end of last year, investors thought the upswing could continue in 2024. So far, this hope has not been confirmed. The main focus for the industry is the refinancing conditions. These have gradually deteriorated, as stubborn inflation is keeping central bank interest rates high. And judging by the wording of central bankers, the next interest rate cut does not seem to be penciled in yet. However, if it happens in the summer, things will likely move quickly for the life sciences sector. Then a quick sector rotation is the order of the day! Here is our buy list for the upcoming event.

Read

Commented by Armin Schulz on May 7th, 2024 | 07:00 CEST

Novo Nordisk, Cardiol Therapeutics, Pfizer - Pharma Watchlist: Three top innovators

  • Biotechnology
  • Pharma

In the rapidly evolving world of biotechnology and the pharmaceutical industry, a single drug can make all the difference, especially when these drugs are unique. They have the potential to change the entire sector by setting new standards in therapy, addressing unmet medical needs, and ultimately improving the quality of life of countless patients worldwide. These drugs are often called blockbusters and generate revenue of more than USD 1 billion. Innovation often also means creating a moat against the competition. Today, we take a look at three companies that are pursuing unique approaches.

Read

Commented by Armin Schulz on May 6th, 2024 | 07:15 CEST

Bayer on the path out of crisis. With their oncology pipelines, are Defence Therapeutics and BioNTech also on the verge of a turnaround?

  • Biotechnology
  • Pharma
  • Cancer
  • Innovations

After several years of stumbling from one crisis to another, pharmaceutical and agrochemical giant Bayer is now showing signs of a recovery on the horizon. As Bayer navigates its long and rocky road out of the crisis, investors and industry experts are now turning their attention to two other exciting biotech companies: Defence Therapeutics and BioNTech. Both companies, which have caused a sensation in the past mainly due to their revolutionary approaches in cancer therapy, could follow in Bayer's footsteps with their promising oncology pipelines, moving from uncertainty to a bright future.

Read

Commented by André Will-Laudien on May 2nd, 2024 | 06:45 CEST

Is it time already? Get out of AI, and buy biotech: Nvidia, Evotec, Defence Therapeutics and Bayer in focus

  • Biotechnology
  • Pharma
  • AI

Another blow to the bottom line! At the end of April, the Nasdaq technology exchange plummeted for the third time, again showing significant weakness at 17,333 points. After a long upward trend of the NDX to just under 18,500 points, an upper limit seems to have been found. Even high-tech favorites such as Nvidia, Super Micro, Meta, and Apple show dangerous reversal points on the chart. At the same time, some stocks in the biotech sector are forming good bottom formations. Is now the time to switch?

Read

Commented by Armin Schulz on April 30th, 2024 | 07:00 CEST

Evotec, Vidac Pharma, BioNTech - The billion-dollar race for cancer therapy

  • Biotechnology
  • Pharma
  • Cancer

Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress are driving revenues in the pharmaceutical industry. This not only underlines the enormous financial value of oncology as an investment area but also promises ground-breaking improvements in patient care. We look at three companies that could benefit from this.

Read

Commented by André Will-Laudien on April 24th, 2024 | 07:00 CEST

Takeover rumors for biotech shares: BioNTech, Formycon, Cardiol Therapeutics and Novo Nordisk in focus

  • Biotechnology
  • Pharma
  • Innovations
  • Cancer

The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is due to high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany's economic conditions are deteriorating dramatically, particularly due to the ongoing geopolitical conflicts. It should, therefore, come as no surprise if the ECB announces an "emergency interest rate cut" in the summer. That would then be the starting signal for a major reshuffle out of the best performers of recent months and into the long-neglected biotech segment. We have selected a few interesting stocks.

Read

Commented by Fabian Lorenz on April 23rd, 2024 | 07:00 CEST

TAKEOVER FEVER for biotech shares! Evotec, Bayer, Vidac Pharma - Who will follow Morphosys?

  • Biotechnology
  • Pharma
  • Innovations
  • Cancer

There is takeover fever in the biotech sector. Genmab recently announced the acquisition of ProfoundBio, the US biotech company developing ovarian and endometrial cancer drugs, for USD 1.8 billion. With Morphosys, the takeover carousel is also turning in Germany. Who is the next candidate? Evotec is often mentioned. Due to unauthorized insider trading, the biotech company's shares have come under fire this year and offer an interesting entry opportunity. Vidac Pharma also impresses operationally. The Company's new approach has the potential to revolutionize cancer treatment. The study results of the past few months are very promising. Bayer shares surprised investors yesterday as one of the day's winners in the DAX. Is the Leverkusen-based company's stock about to take off?

Read

Commented by Juliane Zielonka on April 22nd, 2024 | 07:00 CEST

Cardiol Therapeutics, Bayer AG, Fresenius - Who will be the trendsetter in tomorrow's healthcare market?

  • Biotechnology
  • Pharma
  • Healthcare

The healthcare sector is a lucrative segment for risk-conscious investors. The global healthcare services market size is expected to achieve a compound annual growth rate (CAGR) of 8.96% linkedin.com/pulse/healthcare-services-market-size-share-2023-cmxbc by 2028. Understanding local healthcare needs is the basis for the growth of companies such as Cardiol Therapeutics, Bayer and Fresenius. Cardiol Therapeutics is a promising life sciences company researching several heart diseases with a focus on heart health and developing suitable medication. A disease such as heart failure (HF), for example, affects 26 million people worldwide and offers high scaling potential for the Canadian researchers and developers at Cardiol. Bayer also recognizes the market potential and would like to supply this target group with a gene therapy via Fast Track. Fresenius is familiar with market conditions due to expiring patent protection and is launching a lucrative biosimilar in the US. Which of these three companies will set the trend in the healthcare market of the future?

Read